Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Hold” by Brokerages

Masimo Co. (NASDAQ:MASI) has received a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $137.43.

Several analysts have commented on MASI shares. Jefferies Financial Group reissued a “hold” rating and issued a $121.00 price objective (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Needham & Company LLC downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $148.00 to $170.00 in a report on Monday, April 15th. BTIG Research boosted their price objective on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Finally, StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th.

Masimo Stock Performance

NASDAQ MASI opened at $135.24 on Friday. The stock has a 50-day simple moving average of $135.74 and a two-hundred day simple moving average of $115.95. The firm has a market capitalization of $7.16 billion, a P/E ratio of 89.56 and a beta of 0.97. Masimo has a fifty-two week low of $75.22 and a fifty-two week high of $191.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. The business had revenue of $548.90 million during the quarter, compared to analyst estimates of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company’s revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the business posted $1.32 EPS. On average, equities analysts forecast that Masimo will post 3.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MASI. Riverview Trust Co acquired a new position in Masimo in the 1st quarter valued at $25,000. Massmutual Trust Co. FSB ADV grew its holdings in shares of Masimo by 140.6% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. Byrne Asset Management LLC purchased a new position in Masimo during the 4th quarter valued at about $28,000. NBC Securities Inc. purchased a new position in Masimo during the 3rd quarter valued at about $34,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Masimo by 851.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 264 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.